Immunotherapy - Monoclonal Antibodies
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
142
NCT03644056
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 22, 2018
Completion: May 14, 2020
NCT04306224
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Start: Jun 5, 2020
Completion: Oct 7, 2022
NCT04414163
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Phase: Phase 2
Start: Oct 27, 2020
Completion: Feb 28, 2026
NCT05276310
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Start: Jun 2, 2022
Completion: Aug 30, 2029
NCT06365840
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Start: Jan 13, 2025
Completion: Aug 31, 2029
Loading map...